<DOC>
	<DOCNO>NCT01884922</DOCNO>
	<brief_summary>Multicenter , open label , prospective study include successively phase I trial phase II trial Phase I : Open label , non-randomized , sequential dose escalation drug , vinblastine nilotinib .</brief_summary>
	<brief_title>Study Of Vinblastine Combination With Nilotinib Children , Adolescents Young Adults</brief_title>
	<detailed_description>Low grade glioma ( LGG ) frequent brain tumor type child . They often chemosensitive . However , 50 % tumor progress within first 5 year start treatment need second-line therapy ( Laithier , JCO 2003 ) . In case , patient still young risk side effect radiation therapy call another medical treatment . If tumor respond first-line chemotherapy , prognosis worsens 25 % death within first 5 year optic glioma ( de Haas , Pediatr Blood Cancer 2009 ) . Vinblastine ( Velbe® ) effective drug low grade glioma antiproliferative antiangiogenic effect . An update Canadian phase II weekly vinblastine ( 6 mg/m²/week ) report one complete response ( CR ) , three partial response ( PR ) 9 minor response ( MR ) first 31 patient ( Bouffet , Abstract Neuro-Oncology 2008 ) . The 1-year progressionfree survival ( PFS ) rate 57 % . Tolerance treatment fair allow prolonged maintenance therapy Langerhans cell histiocytosis anaplastic large cell lymphoma ( ALCL ) . These data encourage proceed test approach pediatric low-grade glioma . Nilotinib tyrosine kinase inhibitor ( TKI ) know affect c-Kit , DDR1 PDGF receptor alpha beta . PDGF growth factor normal tumoral astrocyte oligodendrocyte . In addition , PDGF receptor express pediatric low-grade glioma vessel ( McLaughlin , J Pediatr Hematol Oncol 2003 ; Peyrl , Pediatr Blood Cancer 2009 ) . Tumor response class TKI report occasionally ( Peyrl , Pediatr Blood Cancer 2009 ; McLaughlin , J Pediatr Hematol Oncol 2003 ) . When used monotherapy , class TKI well tolerate child , include brain tumor ( Wayne , Blood 2008 ; Baruchel , Eur J Cancer 2009 ; Geoerger , Eur J Cancer 2009 ) . Taking advantage different antiangiogenic mechanism , limited non-overlapping toxicity , vinblastine nilotinib could play interesting role treatment pediatric low-grade glioma . Nilotinib via PDGFRA c-kit interaction may also interfere stroma tumor key factor tumor growth show NF1 mouse model ( Daginakatte , Cancer Res 2008 ; Kim , Neuroscience 2010 ; Simmons , J Neuropathol Exp Neurol 2011 ) . Both drug also immunostimulating effect especially dendritic cell , explore treatment select patient ( Tanaka , Cancer Res 2009 ; Nishioka Immunotherapy 2011 ) Previous phase II assess efficacy combination compare vinblastine single agent , nilotinib vinblastine administer escalate dosage order identify recommend dos agent give combination . This phase I part trial justify possible interaction two drug substrates cytochrome P450 CYP3A4 . Initial/starting dose nilotinib ( 115 mg/m² BID ) 50 % recommend dose use monotherapy adult ( 800 mg/day : 400 mg BID =230 mg/m2 BID ) . Initial/starting dose vinblastine 50 % recommend dose use monotherapy association chemotherapeutic drug ( i.e . 3 mg/m2 week ) . This justify obtain pharmacokinetic data drug use combination . A phase I trial evaluate nilotinib single agent pediatrics hematological malignancy ongoing , run ITCC COG group , explore dose-levels 230 mg/m² 460 mg/m² BID . The result phase I trial , expect 2012 , data current trial consider decide whether high dose-level nilotinib open ( 350 mg/m² BID ) .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Written inform consent sign patient , parent legal representative assent minor child . 2 . Age : 6 month &lt; 21 year age time study entry 3 . Histologically confirm lowgrade glioma nonNF1 patient ( biopsy need study entry ) . For patient NF1 optic pathway glioma , biopsy require confirm radiological diagnosis low grade glioma . 4 . Relapse refractory tumor least one firstline therapy , take account surgery . 5 . Evaluable Disease morphologic MRI 6 . Karnofsky performance status score &gt; =70 % patient &gt; 12 year age , Lansky score &gt; =70 % patient &lt; =12 year age , include patient motor paresis due disease . 7 . Administration stable dose steroid least one week 8 . Life expectancy &gt; = 3 month . 9 . Adequate organ function : Adequate hematopoietic function : neutrophil ³1.0 x 109/L , platelet ³100 x 109/L ; hemoglobin ³8 g/dL Adequate renal function : serum creatinine &lt; 1.5 x ULN age In others case serum creatinine &gt; 1.5 ULN accord age , Glomerular filtration rate creatinine clearance &gt; 70 mL/min/1.73 m2 &gt; 70 % expect value Adequate electrolytes level : potassium , magnesium , phosphor , total calcium Lower Limit Normal ( LLN ) Adequate hepatic function : total bilirubin &lt; =1.5 x ULN ; AST ALT &lt; =2.5 x ULN . Absence peripheral neuropathy &gt; = grade 2 ( Common Toxicity Criteria Adverse Event , NCI CTCAE v4.0 ) Adequate cardiac function : Shortening Fraction ( SF ) &gt; = 28 % ( 35 % child &lt; 3 year ) Left Ventricular Ejection Fraction ( LVEF ) &gt; = 50 % baseline , determine echocardiography Absence QTc prolongation ( QTc &gt; 450 msec baseline ECG , use QTcF formula ) clinically significant ventricular atrial arrhythmia 10 . Washout period least 3 week case preliminary chemotherapy , 6 week case nitrosoureacontaining chemotherapy , 2 week case treatment vincristine 6 week case radiation therapy 11 . Possibility receive therapeutic schedule indicate protocol 12 . Patients reproductive potential must use effective contraception treatment 90 day last dose . Females reproductive potential must negative pregnancy test &lt; = 7 day start Nilotinib and/or Vinblastine . 13 . Patients already treat one two drug enrol trial provide rechallenging drug could consider acceptable 1 . Concomitant antitumor treatment 2 . Not recovered &lt; Grade 2 acute toxic effect prior chemotherapy , immunotherapy radiotherapy 3 . Known intolerance hypersensitivity Vinblastine 4 . Existence another severe systemic disease 5 . Uncontrolled infection responsive antibiotic , antiviral medicine , antifungal medicine , 6 . Any concurrent illness opinion investigator may interfere treatment evaluation patient 7 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption nilotinib . 8 . Simultaneous treatment strong cytochrome P450 CYP3A4 inhibitor ( e.g . antiepileptic drug , see complete list Appendix 5 ) . 9 . Simultaneous treatment antiarrythmic drug drug know prolong QT interval ( cloroquine , halofantrine , clarithromycin , haloperidol , methadone , moxifloxacin , bepridil , cisapride pimozide ) . A list QT prolong compound find http : //www.azcert.org/medicalpros/druglists/druglists.cfm ( Appendix 6 ) 10 . Impaired cardiac function include one following : Clinically significant rest brachycardia ( &lt; 50 beat per minute ) . QTc &gt; 450 msec baseline ECG . If QTc &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc . Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) . History presence clinically significant ventricular atrial tachyarrhythmias ( include congenital long QT syndrome know family history congenital long QT syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Children</keyword>
	<keyword>adolescent</keyword>
	<keyword>young adult</keyword>
</DOC>